[Preoperative treatment of FT-207 suppository in cervical cancer-- serum and tumor tissue content of FT-207].
A 750 mg FT suppository was inserted daily for seven days prior to surgery of uterine cervical carcinoma. The concentrations of FT and 5-FU in the serum, tumor tissue, adjacent normal tissues and regional lymph nodes were then measured. In addition, the concentrations of FT and 5-FU in the serum of patients who had been receiving chemotherapy for long term (an average of 15 months) after the initial remission were measured. The results are as follows: The 5-FU concentration in the serum of patients following short duration of administration was 0.014 +/- 0.006 micrograms/micromilligram. The 5-FU concentration in the tumor tissue was 0.209 +/- 0.132 microgram/g. This was approximately 3.2 times higher than the concentration in the normal tissue which was 0.065 +/- 0.017 microgram/g, and approximately 2.4 times higher than in the regional lymph nodes of 0.088 +/- 0.055 microgram/g. Relatively higher concentrations of 5-FU were seen in the non-keratinizing type than in the keratinizing type suggesting. The correlation between the concentration in the tumor tissue and the histologic findings of the carcinoma tissue. The 5-FU concentration in the serum of patients receiving long-term chemotherapy was 0.019 +/- 0.015 microgram/micromilligram, showing no significant difference from the patients receiving short-term chemotherapy.
D002584:Cervix Uteri / Q000032:analysis; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D013488:Suppositories; D005641:Tegafur / Q000032:analysis* / Q000097:blood / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000032:analysis* / Q000097:blood / Q000188:drug therapy
D013488:Suppositories; D005641:Tegafur; D005472:Fluorouracil